Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Johnson & Johnson Secures EU Approval For ICOTYDE In Plaque Psoriasis

22 September 2026 · By · Wire by Fusion42

Published

22 September 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 23 September 2026 · Fusion42 review

Johnson & Johnson has secured European Union regulatory approval for ICOTYDE, a treatment for plaque psoriasis, expanding its pharmaceutical reach in the dermatology sector within the EU.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Dermatology biotech founders should note the unlocking of EU market access through ICOTYDE’s approval, opening new sales opportunities and competitive benchmarks against established psoriasis treatments.

◆ Coverage

1 source · 22 Sep 2026

◆ Related on Wire

◆ Topics

Biotechdrug-approvalplaque-psoriasisEU-regulationpharma-expansion